Cohort . | Population studied . | Biomarker(s) studied . | Median follow-up . | Outcome . | Biomarker thresholds and results . |
---|---|---|---|---|---|
Thousand & 1 Study (58) | 1,093 individuals with T1D, ≥18 years old, with no known heart disease at baseline | NT-proBNP | 6.3 years | Incident MACE* HF | NT-proBNP >300 pg/mL: 41 per 1,000 person-years NT-proBNP <150 pg/mL: 10 per 1,000 person-years |
Pooled cohort from Atherosclerosis Risk in Communities (ARIC), Dallas Heart Study (DHS), and Multi-Ethnic Study of Atherosclerosis (MESA) (56) | 6,799 individuals with dysglycemia (diabetes 33.2%, prediabetes 66.8%), and no CVD at baseline | NT-proBNP, hs-CRP, and hs-cTN | 17 years | Incident HF: prediabetes vs. diabetes | hs-cTN ≥6 ng/L NT-proBNP ≥125 pg/mL hs-CRP ≥3mg/L Biomarker score= 1 HR1.40 (1.09–1.80) vs. 1.82 (1.31–2.53) Biomarker score = 2 HR 1.83 (1.37–2.45) vs. 2.42 (1.71–3.43) Biomarker score ≥3 HR 3.68 (2.53–5.34) vs. 4.72 (3.16–7.04) |
EXAMINE (57) | 5,224 individuals with T2D and a recent acute coronary syndrome event | NT-proBNP | 597 days | Incident HHF | NT-proBNP 154.1–420.4: HR 3.27 (1.20, 8.92) NT-proBNP 420.4 to <1,084.0: HR 7.24 (2.84–18.49) NT-proBNP ≥1,084.0: HR 29.3 (12.0–71.5) |
St Vincent’s Screening to Prevent Heart Failure (STOP-HF) (59) | 1,374 participants at HF risk, ∼20% with diabetes | BNP | 4.2 years | LV dysfunction or newly diagnosed HF for intensive intervention vs. usual care | At least one BNP >50 pg/mL OR for intervention 0.55 (0.37–0.82); P =0.003 |
NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease (PONTIAC) (60) | 300 individuals with T2D with no history of CVD | NT-proBNP | 2 years | HHF or death | NT-proBNP >125 pg/mL 65% risk reduction with intervention in primary endpoint 40% risk reduction in HHF |
Canagliflozin Cardiovascular Assessment Study (CANVAS) (131,211) | 4,330 individuals with T2D and either CVD or multiple risk factors | NT-proBNP | 6 years | Incident HHF; HHF or death | NT-proBNP ≥125 pg/mL Incident HHF: HR 5.40 (2.67–10.9) HHF or death: HR: 3.52 (2.38–5.20) |
Cohort . | Population studied . | Biomarker(s) studied . | Median follow-up . | Outcome . | Biomarker thresholds and results . |
---|---|---|---|---|---|
Thousand & 1 Study (58) | 1,093 individuals with T1D, ≥18 years old, with no known heart disease at baseline | NT-proBNP | 6.3 years | Incident MACE* HF | NT-proBNP >300 pg/mL: 41 per 1,000 person-years NT-proBNP <150 pg/mL: 10 per 1,000 person-years |
Pooled cohort from Atherosclerosis Risk in Communities (ARIC), Dallas Heart Study (DHS), and Multi-Ethnic Study of Atherosclerosis (MESA) (56) | 6,799 individuals with dysglycemia (diabetes 33.2%, prediabetes 66.8%), and no CVD at baseline | NT-proBNP, hs-CRP, and hs-cTN | 17 years | Incident HF: prediabetes vs. diabetes | hs-cTN ≥6 ng/L NT-proBNP ≥125 pg/mL hs-CRP ≥3mg/L Biomarker score= 1 HR1.40 (1.09–1.80) vs. 1.82 (1.31–2.53) Biomarker score = 2 HR 1.83 (1.37–2.45) vs. 2.42 (1.71–3.43) Biomarker score ≥3 HR 3.68 (2.53–5.34) vs. 4.72 (3.16–7.04) |
EXAMINE (57) | 5,224 individuals with T2D and a recent acute coronary syndrome event | NT-proBNP | 597 days | Incident HHF | NT-proBNP 154.1–420.4: HR 3.27 (1.20, 8.92) NT-proBNP 420.4 to <1,084.0: HR 7.24 (2.84–18.49) NT-proBNP ≥1,084.0: HR 29.3 (12.0–71.5) |
St Vincent’s Screening to Prevent Heart Failure (STOP-HF) (59) | 1,374 participants at HF risk, ∼20% with diabetes | BNP | 4.2 years | LV dysfunction or newly diagnosed HF for intensive intervention vs. usual care | At least one BNP >50 pg/mL OR for intervention 0.55 (0.37–0.82); P =0.003 |
NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease (PONTIAC) (60) | 300 individuals with T2D with no history of CVD | NT-proBNP | 2 years | HHF or death | NT-proBNP >125 pg/mL 65% risk reduction with intervention in primary endpoint 40% risk reduction in HHF |
Canagliflozin Cardiovascular Assessment Study (CANVAS) (131,211) | 4,330 individuals with T2D and either CVD or multiple risk factors | NT-proBNP | 6 years | Incident HHF; HHF or death | NT-proBNP ≥125 pg/mL Incident HHF: HR 5.40 (2.67–10.9) HHF or death: HR: 3.52 (2.38–5.20) |
All HR and OR values are shown with 95% CI. HHF, hospitalization for HF; HR, hazard ratio; hs-cTN, high-sensitivity cardiac troponin; LV, left ventricular; OR, odds ratio.
MACE: hospital admissions for acute coronary syndrome, HF, stroke, and cardiac revascularization and death.